Investigator-initiated Expanded access program for cannabidivarin in seizures associated with autism
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 27 Nov 2018
At a glance
- Drugs Cannabidivarin (Primary)
- Indications Autistic disorder; Seizures
- Focus Expanded access; Therapeutic Use
- 27 Nov 2018 According to a GW Pharmaceuticals media release, initial data (n=5) will be presented at the American Epilepsy Society.
- 21 Feb 2018 According to a GW Pharmaceuticals media release, Open label data from the expanded access IND are expected later in 2018
- 05 Feb 2018 Status changed from planning to recruiting, according to a a GW Pharmaceuticals media release.